Literature DB >> 30007135

Unrecognized prolonged viral replication in the pathogenesis of human RSV infection.

Bindiya Bagga1, L Harrison2, P Roddam3, J P DeVincenzo4.   

Abstract

BACKGROUND: Respiratory symptoms in RSV persist long after the virus is no longer detected by culture. Current concepts of RSV pathogenesis explain this by RSV inducing a long-lasting pathogenic immune cascade. We alternatively hypothesized that prolonged unrecognized RSV replication may be responsible and studied this possibility directly in a human wild-type RSV experimental infection model.
OBJECTIVE: The objective of the current report was to define the duration of true human RSV replication by studying it directly in immunocompetent adults experimentally infected with a clinical strain of RSV utilizing this previously established safe and reproducible model. STUDY
DESIGN: 35 healthy adult volunteers were inoculated with RSV-A (Memphis-37, a low11 passage clinical strain virus, manufactured from a hospitalized bronchiolitic infant) and evaluated over 12 days. Viral load by culture, parallel quantitative PCR (genomic, message) and RSV-specific IgA, were measured twice daily from serially collected nasal washes.
RESULTS: After inoculation, 77% (27/35) of volunteers became RSV infected. As expected, culture-detectable RSV ceased abruptly by the 5-6 t h 15 infection day. However, infected volunteers demonstrated prolonged RSV presence by both genomic and message PCR. RSV-specific IgA rose within respiratory secretions of infected volunteers during same time frame.
CONCLUSIONS: RSV replication appears to continue in humans far longer than previously thought. The rise in nasal RSV-specific IgA shortly after infection likely neutralizes culture detectable virus producing misleadingly short durations of infection. Prolonged viral replication helps explain RSV's extended disease manifestations and increases the potential utility of antivirals.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral; IgA; Mucosal immunity; RSV; Viral load; Viral replication

Mesh:

Substances:

Year:  2018        PMID: 30007135     DOI: 10.1016/j.jcv.2018.06.014

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  2 in total

1.  M1-like, but not M0- or M2-like, macrophages, reduce RSV infection of primary bronchial epithelial cells in a media-dependent fashion.

Authors:  Natalie J Ronaghan; Mandy Soo; Uriel Pena; Marisa Tellis; Wenming Duan; Nooshin Tabatabaei-Zavareh; Philipp Kramer; Juan Hou; Theo J Moraes
Journal:  PLoS One       Date:  2022-10-13       Impact factor: 3.752

Review 2.  A COVID-19 human viral challenge model. Learning from experience.

Authors:  Rob Lambkin-Williams; John P DeVincenzo
Journal:  Influenza Other Respir Viruses       Date:  2020-08-12       Impact factor: 4.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.